Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. – 5. (Cancelled)

6. (Currently amended) Derivatives of compounds Garcinol and Isogarcinol of



~~FORMULA I~~



~~FORMULA II~~



FORMULA I



FORMULA II

respectively, wherein R1, R2 and R3, substituents of Garcinol, and R4 and R5, substituents of Isogarcinol, are selected from a group ~~comprising~~consisting of ~~O-~~Methoxy, ~~O-~~Ethoxy, ~~O-~~Isopropoxy, ~~O-~~Allyloxy, ~~O-~~Butoxy, ~~O-~~t-Butoxy, ~~O-~~Pentoxy, ~~O-~~Hexyloxy, O-CH2-COOH, O-CO-CH2-~~CL~~Cl, O-SO2-CH3, and ~~0-~~O-CH2-CHOH-CH3.

7. (Currently amended) A process for preparation of derivatives of compound ~~g~~Garcinol ~~or~~and Isogarcinol of formula I and II, respectively, said process comprising steps of reacting ~~g~~Garcinol or Isogarcinol with halo compounds to obtain the derivatives with the selected substituents of R1, R2, R3, R4 and R5, at temperature ranging between

30 – 40^{0}C under alkaline conditions in presence of organic solvents, and purifying ~~followed by purification to obtain~~ the derivatives.

8. (Currently Amended) ~~A~~The process ~~for preparation~~ as claimed in claim 7, wherein the reacting process is ~~carrying the reaction~~carried in presence of at least one of alkaline hydroxides or alkaline carbonates.

9. (Currently Amended) ~~A~~The process ~~for preparation~~ as claimed in claim 7, wherein the compounds Garcinol and Isogarcinol are in equimolar concentration.

10. (Currently Amended) ~~A~~The process ~~for preparation~~ as claimed in claim 7, wherein the organic solvent is selected from a group ~~comprising~~consisting of acetone, chloroform, MDC and EDC.

11. (Currently Amended) ~~A~~The process ~~for preparation~~ as claimed in claim 7, wherein the purifying process of the derivatives ~~are~~is ~~purified~~conducted by column chromatograpy.

12. (Currently Amended) A method of treating ~~a~~ diseases ~~condition selected from a group comprising cancer, asthma, cardiac hypertrophy, Acquired Immunodeficiency Syndrome (AIDS), Human Immunodeficiency Virus (HIV)~~ caused by histone acetyltransferase (HAT) in a subject in need thereof, wherein said method comprises a step of administering a pharmaceutically effective amount of the derivatives of compounds Garcinol or Isogarcinol of



~~FORMULA I~~



~~FORMULA II~~



FORMULA I



FORMULA II

respectively to the subject, wherein R1, R2 and R3, substituents of Garcinol, and R4 and R5, substituents of Isogarcinol, are selected from a group ~~comprising~~consisting of ~~O-~~Methoxy, ~~O-~~Ethoxy, ~~O-~~Isopropoxy, ~~O-~~Allyloxy, ~~O-~~Butoxy, ~~O-~~t-Butoxy, ~~O-~~Pentoxy, ~~O-~~Hexyloxy, O-CH2-COOH, O-CO-CH2-~~CL~~Cl, O-SO2-CH3, and ~~O-~~O-CH2-CHOH-CH3 ~~to the subject~~.

13. (Currently Amended) ~~A~~The method as claimed in claim 12, wherein the derivatives are ~~histone acetyl transferase (~~HAT~~)~~ inhibitors.

14. (New) The process as claimed in claim 7, wherein said halo compounds are selected from a group consisting of halogens and HOCO-CH_2-Cl.

15. (New) The method as claimed in claim 12, wherein the diseases caused by HAT are at least one selected from a group consisting of cancer, asthma, cardiac hypertrophy and acquired immunodeficiency syndrome.